Patients with pulmonary nodules eligible for standard minimally invasive lung resection
Conditions
Interventions
Experimental group (Group A):Areola-hidden incision New type of minimally invasive instruments
Control group (Group B):(Uniportal VATS)
Sponsors
Peking University Shenzhen Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: 1.Male or female patients, aged 18-65, with preoperative imaging showing nodules =25%, and intraoperative pathology confirming early-stage lung cancer; 2.A thorough preoperative assessment of areolar mobility, with displacement reaching the anterior axillary line; 3.The cases meet the strict thoracoscopic examination criteria, including anatomical lobectomy (without pleural adhesions, with well-developed fissures) and sublobar resection (including segmentectomy and wedge resection); 4.A comprehensive preoperative evaluation ruled out evidence of locally advanced or metastatic lung cancer; 5.ECOG performance status 0-1; 6.The patient and their family members provide written informed consent to participate in this study.
Exclusion criteria
Exclusion criteria: 1.Patients with a history of lobectomy, preoperative chemotherapy, and/or radiotherapy; 2.Previous breast surgery; combined with breast deformities or active breast disease; 3.Preoperative lung function is impaired; 4.Patients who were also diagnosed with other malignant tumors or severe advanced systemic diseases were excluded; 5.Previous lung infections or uncontrolled acute pulmonary diseases (including acute exacerbations of chronic obstructive pulmonary disease); 6.Severe hypertension (defined as resting systolic/diastolic blood pressure =180/100 mmHg), intracranial tumor, or increased intracranial pressure; 7.Those who have had a recent brain injury, cerebral infarction, or cerebral hemorrhage within the past 6 months; 8.Uncontrolled hyperthyroidism; 9.Has a history of symptomatic angina, myocardial infarction, or heart failure; 10.Significant central nervous system diseases (including psychiatric, neurological, cognitive, or language disorders that affect patient compliance during follow-up); 11.Has a history of chronic pain or long-term use of pain medications; 12.During pregnancy or breastfeeding.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Oncological efficacy: resection margin status and quality of lymph node dissection, including the number of nodes and stations examined.; | — |
Secondary
| Measure | Time frame |
|---|---|
| Quality of life;Perioperative indicators;Cosmetic satisfaction six months after surgery;Record the incidence and severity; | — |
Countries
China
Contacts
Public ContactLi Xiaoqiamng
Peking University Shenzhen Hospital
Outcome results
None listed